Generare

About Generare

Generare operates an industrial‑scale platform that extracts, purifies, identifies, and annotates previously unread microbial metabolites directly from their natural contexts, creating high‑quality molecular data that have never been seen by AI models or researchers. By unlocking the 97% of microbial chemistry hidden from traditional libraries, the company supplies pharmaceutical and biotech partners with novel, evolution‑derived scaffolds for rapid development of first‑in‑class drug candidates across areas such as antibiotics and oncology.

<problem>Drug discovery relies heavily on known chemical libraries, but the vast majority of microbial chemistry—shaped by billions of years of evolution—remains inaccessible, limiting the pool of novel bioactive compounds for new therapeutics.</problem> <solution>Generare provides an industrial-scale platform that extracts, purifies, identifies, and annotates previously unread microbial molecules directly from their natural biological contexts. By unearthing this hidden 97% of microbial chemistry, the company creates unique, high‑quality molecular data that have never been seen by AI models or researchers. Each newly discovered compound is characterized for its natural function, enabling rapid translation into first‑in‑class drug candidates across therapeutic areas such as antibiotics and oncology. The continuously expanding proprietary dataset improves predictive selection, creating a feedback loop that accelerates the discovery of novel, evolution‑derived medicines.</solution> <features> - Large‑scale extraction and purification workflow that isolates native microbial metabolites at industrial throughput - Comprehensive analytical pipeline for structural identification and functional annotation of unknown molecules - Proprietary data generation that adds unique, never‑before‑trained data points to AI‑driven drug discovery models - Integrated platform that links molecule discovery to downstream drug development, supporting rapid lead optimization - Continuous learning loop where each new compound enriches the dataset, enhancing future selection accuracy </features> <target_audience>Generare serves pharmaceutical companies and biotech firms seeking novel, biologically active scaffolds for antibiotic, oncology, and other therapeutic pipelines.</target_audience>

What does Generare do?

Generare operates an industrial‑scale platform that extracts, purifies, identifies, and annotates previously unread microbial metabolites directly from their natural contexts, creating high‑quality molecular data that have never been seen by AI models or researchers. By unlocking the 97% of microbial chemistry hidden from traditional libraries, the company supplies pharmaceutical and biotech partners with novel, evolution‑derived scaffolds for rapid development of first‑in‑class drug candidates across areas such as antibiotics and oncology.

Where is Generare located?

Generare is based in Paris, France.

When was Generare founded?

Generare was founded in 2022.

How much funding has Generare raised?

Generare has raised $5.5M.

Location
Paris, France
Founded
2022
Funding
$5.5M
Employees
35 employees
Investors
Galion ExeTeampactVives Fund
G

Generare

Generare operates an industrial‑scale platform that extracts, purifies, identifies, and annotates previously unread microbial metabolites directly from their natural contexts, creating high‑quality molecular data that have never been seen by AI models or researchers. By unlocking the 97% of microbial chemistry hidden from traditional libraries, the company supplies pharmaceutical and biotech partners with novel, evolution‑derived scaffolds for rapid development of first‑in‑class drug candidates across areas such as antibiotics and oncology.

Paris, FranceFounded 2022355K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.
Updated 2 months ago

Funding

$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

4OTV
Funding rounds are not available yet.

Founders

Product

Problem

Drug discovery relies heavily on known chemical libraries, but the vast majority of microbial chemistry—shaped by billions of years of evolution—remains inaccessible, limiting the pool of novel bioactive compounds for new therapeutics.

Solution

Generare provides an industrial-scale platform that extracts, purifies, identifies, and annotates previously unread microbial molecules directly from their natural biological contexts. By unearthing this hidden 97% of microbial chemistry, the company creates unique, high‑quality molecular data that have never been seen by AI models or researchers. Each newly discovered compound is characterized for its natural function, enabling rapid translation into first‑in‑class drug candidates across therapeutic areas such as antibiotics and oncology. The continuously expanding proprietary dataset improves predictive selection, creating a feedback loop that accelerates the discovery of novel, evolution‑derived medicines.

Target Audience

Generare serves pharmaceutical companies and biotech firms seeking novel, biologically active scaffolds for antibiotic, oncology, and other therapeutic pipelines.

Features

  • Large‑scale extraction and purification workflow that isolates native microbial metabolites at industrial throughput
  • Comprehensive analytical pipeline for structural identification and functional annotation of unknown molecules
  • Proprietary data generation that adds unique, never‑before‑trained data points to AI‑driven drug discovery models
  • Integrated platform that links molecule discovery to downstream drug development, supporting rapid lead optimization
  • Continuous learning loop where each new compound enriches the dataset, enhancing future selection accuracy
1
This profile is AI-generated and may contain inaccuracies.